Apellis Pharmaceuticals Inc APLS shares are trading lower in Wednesday's after-hours session after the company announced a proposed public offering of $300 million of its common stock.
All of the shares are being offered by Apellis. In addition, Apellis expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering.
Apellis is a clinical-stage biopharmaceutical company that's committed to leveraging courageous science, creativity and compassion to deliver life-changing therapies.
APLS 52-Week Range: $27.50 - $73.00
Apellis shares are down 7.28% in after hours trading at $49 at press time.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.